Contact Us

PW Case Review Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Please describe your case:

What injury have you suffered?

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Parker & Waichman, LLP, Files Suit Against Ortho-McNeil Pharmaceutical, Inc. on Behalf of Victim of Ortho Evra Birth Control Patch

37 Year Old Victim Suffered Pulmonary Embolism after Using Ortho Evra for 7 Months

Sep 12, 2005 | PrimeZone
Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to friend Print Page
Parker & Waichman, LLP (http://www.yourlawyer.com) announced that it has filed suit against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc. (NYSE:JNJ), on behalf of a 37 year old woman who suffered a pulmonary embolism after using the Ortho Evra contraceptive patch for seven months.

The suit was filed on September 2, 2005 in the United States District Court for the District of New Jersey in Newark, New Jersey. For more information on Ortho please visit www.orthopatchlawsuit.com

Pulmonary embolism is a type of thromboembolism that occurs when an artery in either lung becomes blocked. In most cases, the blockage is caused by one or more blood clots that travel to the lungs from another part of the body. Usually these clots migrate from the legs but they can also form in the pelvic vein. Pulmonary embolism is potentially fatal or may result in pulmonary arterial obstruction, pulmonary obstruction, pulmonary infarction, chronic pulmonary hypertension, dyspenea and tachypnea. 

Symptoms may include shortness of breath, difficulty breathing, anxiety, chest pain, fainting and convulsions.  Treatment may include long term use of anticoagulant medications. Recent reports have indicated that the risk of developing blood clots, pulmonary embolism, heart attack and stroke may be significantly higher with the Ortho Evra patch than with oral contraceptive use.

It is alleged that Ortho-McNeil was aware of the increased medical risks associated with Ortho Evra before the drug was approved and that, once approved, the company failed to adequately warn patients about these risks. Evidence shows that the risk of blood clots, heart attack and stroke associated with Ortho Evra is significantly higher than with oral contraceptive pills. The incidence of embolisms and thrombotic injuries in Phase III trials of Ortho Evra was reportedly six times greater than the incidence of such events in oral contraceptives using the hormone levonorgestral.

The FDA has logged 9,116 reports of adverse reactions to the patch in a 17 month period, whereas Ortho Tri-Cyclen, a birth control pill, only generated 1,237 adverse reports in a six year period.
 During a 12 month period, 44 serious injuries or deaths have been associated with Ortho Evra, whereas only 17 such reports were linked to the birth control pill during a similar time period.  The pattern is further magnified when usage rates are considered: Ortho Tri-Cyclen has six times the number of users as Ortho Evra.

Prior to approval, the FDA medical review expressed concerns about Ortho Evra causing venous thromboembolisms, stating: “Post-marketing surveillance for DVT (Deep Venous Thrombosis) and PE (Pulmonary Embolism) events will be important, as there are potential serious adverse risks (with two cases of pulmonary emboli in the clinical trials) with this new delivery system for contraception.”

Unlike the birth control pill, which is ingested and metabolized by the body’s digestive system, the medication in the Ortho Evra patch is released directly into the bloodstream.  This may result in dangerously higher concentrations of the medication in the body, leading to adverse effects.

Ortho Evra is an adhesive, transdermal birth control patch that is worn on the torso. The patch is intended to release 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol into the bloodstream per 24 hours. It is replaced once a week for three weeks, and no patch is worn during the fourth week during menstruation.  The regimen is then repeated. Ortho Evra was approved by the FDA in April 2002, and over 4 million women have used Ortho Evra since its approval. Ortho Evra continues to be marketed aggressively to both consumers and physicians.

About Parker & Waichman, LLP

Parker & Waichman, LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide, with offices in New York and New Jersey. Parker & Waichman, LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective medications and medical devices. For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-YOURLAWYER (1-800-968-7529).

Contact:
        
Parker & Waichman, LLP
Jason Mark, Esq.
Melanie H. Muhlstock, Esq.
1-800-YOURLAWYER  - 1-800-968-7529 - toll-free
info@yourlawyer.com
http://www.yourlawyer.coM
Tags:  
Related articles
Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5 VendorsBay Inc